Point72 Asset Management
ANIX icon

Point72 Asset Management’s Anixa Biosciences ANIX Stock Holding History

Point72 Asset Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.6K Sell
17,276
-13,780
-44% -$40.8K ﹤0.01% 3666
2025
Q4 		$96.9K Buy
+31,056
New +$127K ﹤0.01% 3742

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Point72 Asset Management's ANIX Position: Q1 2026 in Review

Point72 Asset Management reduced its Anixa Biosciences (ANIX) stake by 44% in Q1 2026, selling an estimated $40.8K and leaving 17,276 shares worth $44.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3666.

Point72 Asset Management first reported a position in ANIX in Q4 2025 and has held it in 2 quarters since. The position peaked at $96.9K in Q4 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Point72 Asset Management held 17,276 shares of Anixa Biosciences worth $44.6K as of Q1 2026.
  • Point72 Asset Management sold 13,780 Anixa Biosciences shares in Q1 2026, an estimated $40.8K.
  • Anixa Biosciences made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3666 holding.
  • Point72 Asset Management first reported a position in Anixa Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Point72 Asset Management's Anixa Biosciences position peaked at $96.9K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.